Yong Xie

机构：Nanchang University, HEC Pharm (China), Sunshine Hospital, First Affiliated Hospital of Nanchang University · ORCID：0000-0002-5290-5579

发表论文 156 篇 · 总被引 4036 次 · h-index 35

代表论文

• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (2023 · The Lancet Diabetes & Endocrinology · 被引 122)
• Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial (2024 · The Lancet Microbe · 被引 40)
• Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial (2024 · Nature Communications · 被引 24)
• Comprehensive analysis of the function of helicobacter-associated ferroptosis gene YWHAE in gastric cancer through multi-omics integration, molecular docking, and machine learning (2023 · APOPTOSIS · 被引 22)
• Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta‐analysis (2023 · Helicobacter · 被引 14)
• Association between Helicobacter pylori infection and triglyceride levels: a nested cross-sectional study (2023 · Frontiers in Endocrinology · 被引 11)